Max
Kholin

The lawyer who decided aging was a physics problem

Most people who want to stop aging start with biology. Maxim Kholin started with contracts. His MA in Financial Management and Law from Moscow Financial University in 2001 led to over a decade navigating international intellectual property law and corporate transactions - the kind of work that makes you intimately familiar with what big institutions want, how deals get done, and where the leverage lives.

That background, unglamorous from the outside, turned out to be exactly right for what came next. When Kholin co-founded Quantum Pharmaceuticals - a structure-based drug design company - he wasn't the scientist in the room. He was the person who knew how to translate science into deals with top-20 global pharma companies and academic licensing partners. The science was someone else's. Making it commercially real was his.

In 2015, he met Peter Fedichev, a theoretical physicist with a PhD from the University of Amsterdam who'd spent years studying ultracold quantum systems. Their collaboration became Gero - and their central idea was strange enough to make most biology labs uncomfortable: aging, they argued, is fundamentally a problem in non-equilibrium thermodynamics. Not a disease. Not a genetic program. A physics problem. Bodies lose resilience the way physical systems approach critical points - and that loss of resilience is measurable, predictable, and potentially interruptable.

That framing - later formalized as "Gerophysics" - wasn't just academic positioning. It changed what data they looked for, what models they built, and what kinds of interventions might work. By training their AI platform on over 100 million longitudinal medical records, Gero could watch how real human bodies age in real time, not in petri dishes. The result was one of the deepest computational views into human aging that exists anywhere.

Kholin's job in all of this was never to be the physicist. It was to turn the physics into a company. Corporate affairs, legal strategy, investor relations, strategic partnerships - the work that keeps a science-first startup alive long enough to be proven right. When Gero closed a $6 million Series A extension in October 2023, with participation from VitaDAO and EPAM founder Leonid Lozner, Kholin had built something fundable from an idea that sounded, to many, like science fiction.

The Pfizer partnership for fibrotic disease target identification arrived in early 2023. The Chugai deal - a joint research and license agreement for novel antibody therapeutics targeting age-related diseases, with up to $250 million in potential milestone payments - followed in July 2025. Two of the largest names in global pharma, betting on a physics-informed AI platform built on a theory most biologists found eccentric a decade ago.

Gero operates out of Singapore and Palo Alto simultaneously, with a team spread across five continents. In the lab, the results are accumulating: mouse studies showing reductions in frailty indices, improvements in senescence markers, increased synaptic plasticity, and improved survival - effects that persisted two months after treatment stopped. In 2024, Nature published a dedicated Gerophysics collection co-edited by Fedichev and longevity expert Brian K. Kennedy, cementing the field as a standalone scientific discipline. What started as a contrarian idea now has its own section in one of the world's most prestigious scientific journals.

Kholin's contribution to all of this is easy to underestimate. He doesn't run the physics. He doesn't publish the papers. What he does - building the commercial infrastructure around an idea that needs both scientific credibility and deal-making discipline to reach patients - is what separates a research project from a company. In an industry where visionary scientists routinely fail at the business side, Kholin represents the rare complementary half that makes the whole thing work.